1. HBW Insight
  2. >>Wellness
  3. >>Policy & Regulation
  4. >>Regulation

USDA Examines Potential Production Regulation Changes To Prevent Powder Formula Contamination

 
• By Malcolm Spicer

USDA Food Safety and Inspection Service’s National Advisory Committee on Microbiological Criteria for Foods schedules hearing for 15 November to consider a report from FDA on presence of Cronobacter species bacteria in powder formula products.

• Source: Shutterstock

The US Department of Agriculture wants suggestions for changes in powder infant formula manufacturing to decrease the risk of a repeat of the contamination problem which has disrupted the country’s supply chain for the products since early in 2022.

The USDA is asking for answers form the Food and Drug Administration, which has had to take significant steps in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

Latest OTC Eye Drop Production Problem In US Prompts Firm To Close Doors After Recalls

 
• By Malcolm Spicer

BRS Analytical Services in St. Louis recalled more than 75,000 cases of redness and lubricating eye drops and committed “to permanently cease production of all drugs.”

‘You Are Very Regulated’: Consumer Health And Beauty Industries’ Attention Needed In California

 
• By Malcolm Spicer

Regulations likely holding consumer product firms’ attention include the Plastic Pollution Prevention and Packaging Producer Responsibility Act, SB 54, scheduled to become effective by 2027. “Easily the most significant, extended producer responsibility law ever to pass in the world,” says lobbyist

US FDA Independence Questioned At CDC Oversight Hearing

 
• By Michael McCaughan

A Senate committee is investigating leadership changes at the US Centers for Disease Control and Prevention. While the primary focus is vaccine policy, the first hearing suggested the probe could raise questions about FDA independence.

NPA On Clock To Continue Challenge To FDA ‘Drug Preclusion’ Policy For Dietary Ingredients

 
• By Malcolm Spicer

FDA rejects NPAs arguments for clarity on when it recognizes start of investigational new drug programs and what constitutes “substantial clinical investigations” for an IND. Clock starts after FDA met twice-extended deadline to provide answers to NPA’s questions in a 2023 petition.

More from Policy & Regulation

Senate’s Proposed Agreement To End US Shutdown Would Cut FDA Non-User Fee Funding

 
• By Derrick Gingery

But the Senate’s reduction would not be as much as the House of Representatives and President Trump proposed earlier this year, which is likely a win for the agency.

New Magnesium Source For Use In Supplements Approved In EU

 
• By Tom Gallen

The European Commission has added magnesium L-threonate to the list of vitamin and mineral substances which may be used in the manufacture of dietary supplements.

State AGs Say Synthetic Hemp ‘Threatens Public Health,’ Ask Congress To Redefine De-scheduled

 
• By Malcolm Spicer

State and territory attorneys general urge congressional leaders to clarify definition of hemp, which they say “bad actors have exploited due to a perceived loophole” of 0.3% delta-9 THC level stated in 2018 farm bill de-scheduling as controlled substances some ingredients extracted from cannabis.